SENZIME AB ORD - SNZZF STOCK NEWS

Senzime secures a three-year GPO contract with a major US hospital system as the sole source supplier for the TetraGraph monitoring system. The agreement grants access to over 40 hospitals across 11 US states, serving 12.5 million patients annually. Senzime's CEO highlights the significance of being the exclusive supplier to one of the largest IDNs in the US market, emphasizing the validation of their technology and commitment to patient safety. The TetraGraph system aids anesthesiologists in accurately administering neuromuscular blocking drugs during surgery, ensuring patient safety and optimal recovery.

Senzime AB (SNZZF) announces the publication of its 2023 annual and sustainability report, highlighting a remarkable 150% revenue increase to 36 million SEK. The growth was fueled by significant hospital contract wins and sensor sales. CEO Philip Siberg expressed optimism about the company's performance in 2023.

Senzime, a leader in perioperative patient monitoring solutions, secures a significant contract with the US Department of Veterans Affairs to provide TetraGraph Systems. The contract with the North Florida/South Georgia Veterans Health System marks a milestone in expanding Senzime's reach in the US healthcare market. The TetraGraph system aids anesthesiologists in administering drugs accurately, enhancing patient safety post-surgery. CEO Philip Siberg expresses pride in the partnership, highlighting Senzime's dedication to advancing perioperative care for US veterans.

Senzime AB (PUBL) has announced its Annual General Meeting to be held on May 16, 2024. Shareholders must register by May 7, 2024, and notify their attendance by May 14, 2024. The agenda includes resolutions on financial statements, board remuneration, election of board members, and introduction of incentive programs. The Company aims to enhance clinical precision and healthcare management through its innovative medical technology solutions.

Senzime (SNZZF) announces new contracts with top US hospital systems for its TetraGraph system, catering to pediatric and robotic surgery needs. The market opportunity exceeds 20,000 patients per year. The company's focus on neuromuscular monitoring aligns with new clinical guidelines, showcasing solid results and expanding US presence.

Senzime (SNZZF) secures its largest hospital win in the US market, providing over 250 TetraGraph systems to a leading Houston-based university hospital system. The deal is expected to generate over 50 MSEK in revenue over five years, showcasing the company's growth potential in the patient monitoring solutions sector.

Senzime AB (SNZZF) released its Year-end report for January - December 2023, showing significant growth in net sales, gross margin, and expansion in the US market. Financial data revealed a 155% increase in net sales, reaching TSEK 35,754, with a gross margin of 69.8%. EBITDA stood at TSEK -116,793, and earnings per share at SEK -1.45. The CEO highlighted a commercial breakthrough in 2023, with sales surging by 150% to approximately SEK 36 million, driven by new contracts and increased recurring sensor sales. The company aims for each TetraGraph system to generate SEK 50,000 per year in recurring sensor sales. The US-market showed rapid growth, with sales quadrupling in the fourth quarter. Gross margin improved to 70.8% in Q4 and 69.8% for the full year.

Senzime (SNZZF) invites investors, analysts, and media to a webcast presentation of the fourth quarter report for 2023 on February 15, 08:30 CET. The presentation will be held by CEO Philip Siberg and followed by a Q&A session moderated by Erik Palin, analyst at Erik Penser Bank. The live webcast can be accessed at the given link, with a recording available on senzime.com/investors. Contact information for CEO Philip Siberg and CFO Slavoljub Grujicic is provided for further inquiries.

Senzime (STO:SEZI)(OTCQX:SNZZF) announced that Fukuda Denshi, its licensee in the Japanese market, is launching the first integrated TetraGraph module. The new NH-100 module, powered by Senzime's TetraGraph technology, is marketed as an integrated solution for bedside patient monitors to facilitate EMG-based neuromuscular monitoring in the operating room. The module connects to Senzime's TetraSens disposable sensors and is initially sold as an accessory in Japan to the Dynascope 1000 series DS-1200 system used for bedside patient monitoring of vital signs. Senzime has a license agreement with Fukuda Denshi, a leader in the patient monitoring market with annual sales exceeding US$ 1 billion, generating revenues through manufacturing of certain products, product sales, and royalty compensation based on actual sales in the Japanese market.